The approximately 8500 EVD survivors from the 2013–2016 West African outbreak and the rise in EBOV persistence stemming from this large cohort of survivors [6,7,8,9,10] highlights the importance of having an animal model to study persistent infections in immunoprivileged sites, and possibly by studying EBOV/Makona-rgMA-infected mice, this may help shed more light on this topic. The gene discussed is RGMA; the disease is infection.